Research and consulting firm GlobalData reports that Mexico’s health-care market, including both the pharmaceutical and medical device sectors, will be worth about US$27.9 billion by 2020. The overall increase will apparently represent a compound annual growth rate of 6.8 percent from a base of $17.6 billion in 2013. GlobalData attributes the anticipated growth to non-communicable disease prevalence, regulatory improvements, government support for these industries, and the North American Free Trade Agreement. According to GlobalData’s Joshua Owide, “Over 350 domestic and multinational companies are engaged in the manufacture of pharmaceutical products in Mexico. . . . During the next five years, the pharmaceutical sector will have the opportunity to expand, due to a number of branded drugs losing market exclusivity.” See GlobalData News Release, August 7, 2014.